Loading
A phase 3 trial testing IMA203 in melanoma, now recruiting.
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma is a phase 3 interventional study registered as NCT06743126, led by Immatics US, and recruiting on the registry. Official title: A Prospective, Multicenter, Open-label, Randomised, Actively Controlled, Parallel-group Phase 3 Clinical Trial to Evaluate Efficacy, Safety, and Tolerability of IMA203 Versus Investigator's Choice of Treatment in Patients With Previously Treated, Unresectable or Metastatic Cutaneous Melanoma (ACTengine® IMA203-301). Planned enrolment is 360 participants (estimated). The study started in 2025-01-14 and primary completion is expected in 2028-01. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma.
Shares IMA203, Immatics, Advanced melanoma (unresectable stage III and stage IV), Melanoma.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/